All In Biotech

Drug Trial Radar · NCT04464980

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

NIDA-CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,516 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,516

Actual

Start

Jun 8, 2021

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
New York State Psychiatric Institute; Columbia University; Harvard Medical School (HMS and HSDM); Mclean Hospital; National Institute on Drug Abuse (NIDA); The Emmes Company, LLC
First posted
Jul 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

Conditions

  • Opioid Use Disorder (OUD)

Interventions

  • SL-BUPDrug

    Daily dosing of sublingual buprenorphine-naloxone

  • XR-BUPDrug

    Weekly/monthly dosing of extended-release injectable buprenorphine

  • XR-NTXDrug

    Monthly dosing of extended-release injectable naltrexone

  • MMBehavioral

    MM consists of standard Medical Management and the usual counseling at the treatment program.

  • MMRBehavioral

    MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

  • MMDBehavioral

    MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Retention: Continuous retention in MOUD treatment through 26 weeksTime frame: Retention: from randomization through week 26
  2. Discontinuation: Completed Discontinuation without RelapseTime frame: Discontinuation: from randomization through week 24 follow up

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)

    Little Rock, Arkansas

  • Tarzana Treatment Centers, Inc.

    Tarzana, California

  • Liberation Programs, Inc.

    Bridgeport, Connecticut

  • Operation PAR

    Clearwater, Florida

  • Gateway Community Services

    Jacksonville, Florida

  • Aspire Health Partners

    Orlando, Florida

  • Mountain Manor / Maryland Treatment Centers

    Baltimore, Maryland

  • McLean Hospital

    Belmont, Massachusetts

  • Stanley Street Treatment and Resources, Inc.

    Fall River, Massachusetts

  • Square Medical Group, LLC

    Newton, Massachusetts

  • Gibson Center for Behavioral Change

    Cape Girardeau, Missouri

  • Dartmouth Hitchcock - ATP

    Lebanon, New Hampshire

  • University of New Mexico Addiction and Substance Abuse Program

    Albuquerque, New Mexico

  • Bellevue Hospital Center

    New York, New York

  • Adapt Integrated Health Care

    Roseburg, Oregon

  • Adapt Integrated Health Care

    Winston, Oregon

  • Center for Psychiatric and Chemical Dependency Services (CPCDS)

    Pittsburgh, Pennsylvania

  • Internal Medicine Recovery Engagement Program (IM-REP)

    Pittsburgh, Pennsylvania

  • Shoreline Behavioral Health Services

    Conway, South Carolina

  • Huntsman Mental Health Institute / University of Utah

    Salt Lake City, Utah

  • Chestnut Ridge Center

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.